Myriapod NGS Archivi - Diatech

22 03, 2024

Albino Eccher et al., Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing

adlitterio663392024-04-10T12:56:50+02:00

19 03, 2024

Marco Capezzone et al., Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer

adlitterio663392024-03-19T12:51:12+01:00

20 02, 2024

Fabio Canino et al., Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

adlitterio663392024-02-20T14:28:58+01:00

19 01, 2024

Marcella Barbarino et al., Comparison of two mechanical disaggregation methods of fresh lung tissues for extraction of high-quality RNA

adlitterio663392024-01-19T14:43:41+01:00

1 01, 2024

Andrea Boscolo Bragadin et al., Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patients

adlitterio663392024-01-01T14:40:45+01:00

23 08, 2023

Maria Raffaella Ambrosio et al., Immune landscape and oncobiota in HPV-Associated Colorectal Cancer: an explorative study

adlitterio663392023-08-23T09:33:37+02:00

1 08, 2023

Caterina Fumagalli et al., Molecular testing in indeterminate thyroid nodules: an additional tool for clinical decision-making

adlitterio663392023-08-01T09:38:22+02:00

28 07, 2023

Leo Guidobaldi et al., Primary Thyroid Lymphoma: How Molecular Biology and Ancillary Techniques Can Help the Cytopathologist Overcome This Diagnostic Challenge

adlitterio663392023-07-28T09:29:08+02:00

14 07, 2023

Alessandro Pancrazzi et al., BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings

adlitterio663392023-10-17T09:23:04+02:00

16 05, 2023

Daniela Massi et al., Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group.

adlitterio663392023-10-17T09:13:03+02:00